Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) was the recipient of a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 520 shares, a growth of ∞ from the July 30th total of 0 shares. Based on an average trading volume of 415 shares, the short-interest ratio is currently 1.3 days.
Silence Therapeutics Stock Performance
Shares of Silence Therapeutics stock opened at $4.00 on Tuesday. The stock has a 50 day moving average of $2.70 and a 200 day moving average of $2.13. Silence Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $5.99.
Silence Therapeutics Company Profile
Silence Therapeutics is a clinical-stage biotechnology company focused on the development of small interfering RNA (siRNA) therapies designed to silence disease-causing genes. The company’s proprietary AtuRNAi platform employs ligand-conjugated siRNA to enable targeted delivery and extended duration of action, with the aim of addressing chronic and severe diseases. Silence Therapeutics advances its own pipeline programs while also forming strategic partnerships to leverage its delivery technology in indications such as cardiovascular disease, metabolic disorders and rare genetic conditions.
The company’s lead program, SLN360, is designed to reduce lipoprotein(a), a known independent risk factor for cardiovascular events, and is currently in clinical development.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
